Trevi Therapeutics
Clinical trials sponsored by Trevi Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to silence stubborn chronic cough Results expected Sep 2027 (estimated)
-
Could a painkiller stop the cough that Won't quit in lung fibrosis?
Symptom relief Recruiting nowThis study tests whether an extended-release form of nalbuphine, a pain medication, can safely reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a lung scarring disease. About 306 adults with IPF and a cough lasting at least 8 weeks will receive either t…
Phase 3 • Sponsor: Trevi Therapeutics • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
New pill aims to silence stubborn chronic cough
Symptom relief Recruiting nowThis study tests a new extended-release tablet called nalbuphine for people with refractory chronic cough—a cough that persists despite treatment. About 100 adults will receive either the drug or a placebo for 6 weeks. The main goal is to see if the drug reduces how often people …
Phase 2 • Sponsor: Trevi Therapeutics • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC